Surgery Partners executive sells over $196k in company stock

Published 04/09/2024, 21:16
Surgery Partners executive sells over $196k in company stock

Surgery Partners, Inc. (NASDAQ:SGRY) National Group President Harrison R. Bane has recently engaged in significant transactions involving the company's stock, according to a new SEC filing. Bane sold 6,325 shares of common stock at prices ranging from $31.1054, amounting to a total of $196,741. This sale was conducted to satisfy tax withholding obligations related to the vesting of restricted stock.

In addition to the sale, Bane also acquired 1,251 shares of common stock as restricted stock awards (RSAs) valued at $31.95 per share, totaling $39,969. These RSAs are set to vest in three equal annual installments starting from the first anniversary of the grant date.

Following these transactions, Bane's holdings in Surgery Partners have adjusted to 48,236 shares of common stock. The sale of shares was particularly notable as it was executed to fulfill the tax obligations that come with the vesting of restricted stock, a common practice among executives.

Investors often keep an eye on insider transactions as they can provide insights into an executive's view of the company's stock value and financial health. Surgery Partners, Inc., based in Brentwood, Tennessee, operates in the healthcare sector, providing services through a range of surgical facilities across the United States.

For those tracking insider activity as an indicator of corporate confidence, the latest moves by Bane at Surgery Partners will be of interest, particularly as they balance both acquisition and disposition of shares within a short period.

"In other recent news, Surgery Partners, Inc. reported a significant increase in its Q2 2024 financials, with net revenue reaching $762 million, a 14.2% increase from the previous year, and adjusted EBITDA growing by 18% to $118.3 million. These figures were bolstered by a nearly 4% rise in surgical case volume and a strategic focus on higher acuity procedures. The company also reported earnings of $83 million, in line with expectations, and deployed $280 million in capital for acquisitions and investments. In addition to these financial developments, Surgery Partners has announced a change in its financial oversight structure, appointing Ernst & Young LLP as its new independent registered public accounting firm, marking a departure from its previous auditor, Deloitte & Touche LLP. This transition is part of the company's continuous effort to maintain the highest standards of financial reporting and auditing. In addition, Surgery Partners has raised its 2024 net revenue outlook to over $3.075 billion and adjusted EBITDA to more than $508 million, indicating a positive outlook for the company's financial future. These are some of the recent developments shaping the trajectory of Surgery Partners, Inc."

InvestingPro Insights

As investors monitor insider transactions for clues about executive sentiment, the financial metrics and future projections for Surgery Partners, Inc. (NASDAQ:SGRY) provide additional context for these moves. With a market capitalization of $3.92 billion, the company's stock price movements have been notably volatile, which aligns with an InvestingPro Tip highlighting the stock's recent fluctuations.

Despite not being profitable over the last twelve months, an InvestingPro Tip suggests that analysts expect net income growth for Surgery Partners this year, painting a picture of potential turnaround. This is further supported by the company's recent revenue growth of 8.55% over the last twelve months as of Q2 2024, and a more impressive quarterly revenue growth of 14.16% in Q2 2024, indicating a positive trajectory in the company's operations.

Moreover, Surgery Partners has seen a strong return of 21.82% over the last three months, which is likely to attract investor attention. This performance is particularly noteworthy given that the company does not pay a dividend, suggesting that investors are looking to capital appreciation as a primary return on investment.

For more in-depth analysis and additional InvestingPro Tips on Surgery Partners, investors can visit https://www.investing.com/pro/SGRY, where seven more tips are available to provide a comprehensive understanding of the company's financial health and stock performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.